Silibinin anti-tumor effects at a glance

Silibinin is a major component of silymarin (Silybum marianum), which has traditionally been used to treat a wide range of liver diseases. Recently, Silibinin and its derivatives in both in vitro and in vivo models have shown a significant inhibitory effect in different types of tumors including skin, breast, lung, colon, bladder, prostate, kidney and liver. The chemo-preventive potentials of this flavonoid are promoted by inducing apoptosis, enhancing tumor suppressor and cell cycle inhibitors, inhibiting growth factors, and attenuating proliferative mediators. In this paper, a summary of the important molecular mechanisms involved in Silibinin anti-cancer effects, animal studies and important clinical trials have been presented. The results of these studies will provide a more comprehensive perspective of Silibinin and help to optimize its effects in cancer chemotherapy.

Autorentext

Mahdi Mashhadi Akbar Boojar (Pharm.D., Ph.D.) promovierte 2016 in Pharmakologie an der Teheraner Universität für medizinische Wissenschaften, Iran. Dr. Mahdi Mashhadi Akbar Boojar arbeitet derzeit in der Abteilung für Pharmakologie und Toxikologie der Baqiyatallah-Universität für medizinische Wissenschaften in Teheran, Iran.